Research programme: anti-PSCA monoclonal antibodies - Agensys/Merck

Drug Profile

Research programme: anti-PSCA monoclonal antibodies - Agensys/Merck

Latest Information Update: 24 Aug 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agensys
  • Developer Amgen
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Aug 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 08 Sep 2008 Preclinical development is ongoing in USA
  • 17 Oct 2005 Agensys and Merck & Co have entered into an agreement to co-develop and co-promote compounds arising from this research programme worldwide for prostate cancer as well as additional cancer indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top